Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Pursuant to Regulation 30 and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of the newspaper notice in the interest of the shareholders regarding the intimation of 39th Annual General Meeting of the Company scheduled to be held on Thursday, July 25, 2024, at 11:00 a.m. (IST) through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM"), published in the "The Economics Times, Free Press Journal, Maharshtra Times and Navshakti" newspaper on June 29, 2024.
01-07-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Closure of Trading Window

This is to inform you that pursuant to the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enanctment(s) thereof, for the time being in force) and in accordance with the Code of Internal Procedures and Conduct for Regulating, Monitoring, and Reporting of Trading by Designated Persons, the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited ("the Company") will remain closed for Insiders, Designated Persons and their immediate relatives of the Company with effect from Monday, July 01, 2024 till completion of 48 hours after the announcement of the Unaudited Financial Results of the Company for the quarter ended on June 30, 2024 generally made availabe to the public.
28-06-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Intimation Regarding The Appointment Of Additional Non-Executive Independent Director

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that, subject to approval of shareholders in ensuing 39th Annual General Meeting and based on recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company through circular resolution approved on June 22, 2024 have appointed Dr. Nandkumar Kashinath Chodankar (DIN:02736718) as a Additional Director in the category of Non-Executive Independent Director of the Company for a period of 5 yrs w.e.f. June 22, 2024. Please find enclosed the intimation is this regard.
22-06-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Disclosure pursuant to Regulation 30 of the SEBI LODR Regulations 2015 is enclosed.
21-06-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Credit Rating

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CSD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we would like to inform you that, CRISIL Ratings Limited vide its press releases dated June 19, 2024 bearing ref. no. RL/GDS2784/346423/BLR/0624/91401, has reaffirmed/assigned the ratings outstanding for the debt instruments/facilities of the Company, and the rating actions by CRISIL Ratings on the ratings as on date. Enclosed herewith intimation on the same.
19-06-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on June 10, 2024, has approved the allotment of 1,45,000 equity shares of the face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 ("Bliss GVS ESOP-2019").
10-06-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Reg.24(A)-Annual Secretarial Compliance

Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201, please find enclosed herewith the Annual Secretarial Compliance Report of the Company for the financial year ended March 31, 2024.
29-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held on May 15, 2024, has approved the allotment of 46,750 equity shares of the face value of Re. 1/- each to the eligible employees who have exercised their stock options under Bliss GVS Pharma Limited-Employee Stock Option Plan 2019 (''Bliss GVS ESOP-2019'').
15-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

According to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclsoure Requirements) Regulations, 2015, please find enclosed herewith the copies of the newspaper advertisement published regarding the extract of the statement of audited standalone and consolidated financial results for the quarter and year ended March 31, 2024 in "The Economic Times & The Free Press Journal" an English Daily and "Maharashtra Times & Navshakti" a Regionally Daily, on May 04, 2024.
06-05-2024
Bigul

BLISS GVS PHARMA LTD. - 506197 - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclsoure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with Para B of Part A of Schedule III of SEBI Listing Regulations, we would like to inform you that the Members of Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company") in its meeting held on today i.e. May 02, 2024 has granted 7,56,000 Stock Options under Bliss GVS Pharma Limited-Employee Stock Options Plan 2019 to the eligible employees of the Company.
02-05-2024
Next Page
Close

Let's Open Free Demat Account